Research suggests that interventions like plasma apheresis could serve as promising anti-aging therapies by reducing systemic inflammation and potentially extending health span.

SASP components, including pro-inflammatory cytokines and growth factors, contribute to 'inflammaging,' affecting diseases like cardiovascular issues and neurodegeneration.

SASP factors can degrade the extracellular matrix and promote fibrosis in organs, worsening conditions such as pulmonary fibrosis and chronic kidney disease.

Furthermore, SASP factors interfere with immune surveillance, allowing malignant cells to persist and thereby facilitating cancer progression.

Aging alters plasma composition by increasing pro-inflammatory cytokines and decreasing protective factors, which can affect the success of therapies like apheresis in older individuals.

Cellular senescence and the associated secretory phenotype (SASP) play a significant role in aging and age-related diseases by promoting chronic inflammation and functional decline.

Cellular senescence involves irreversible growth arrest in response to stress, and the buildup of these cells can disrupt tissue homeostasis, accelerating deterioration with age.

Therapeutic strategies such as apheresis aim to target SASP by removing harmful factors from circulation, which may help mitigate age-associated pathologies and restore healthier plasma conditions.

Chronic inflammation driven by SASP impairs stem cell function, hampers tissue repair, and increases vulnerability to degenerative diseases, impacting muscle regeneration and immune health.